A. Salnikov

VEGF expression by mesenchymal stem cells contributes to angiogenesis in pancreatic carcinoma

H. Friess, M. Büchler, A. Apel, 2008, British Journal of Cancer.

MA 19.03 Nintedanib + Pemetrexed/Cisplatin in Malignant Pleural Mesothelioma (MPM): Phase II Biomarker Data from the LUME-Meso Study

M. Socinski, G. Scagliotti, N. Pavlakis, 2017 .

Association of Consensus Molecular Subtypes and Molecular Markers With Clinical Outcomes in Patients With Metastatic Colorectal Cancer: Biomarker Analyses From LUME-Colon 1.

E. Van Cutsem, H. Lenz, F. Ciardiello, 2020, Clinical colorectal cancer.

Antibody targeting of CD24 efficiently retards growth and influences cytokine milieu in experimental carcinomas

T. Schlange, P. Altevogt, I. Herr, 2013, British Journal of Cancer.

Combined treatment of L1CAM antibodies and cytostatic drugs improve the therapeutic response of pancreatic and ovarian carcinoma.

P. Altevogt, A. Krüger, S. Sebens, 2012, Cancer letters.

Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma.

H. Einsele, E. Rasmussen, J. Kalabus, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

S825 EVALUATION OF AMG 420, AN ANTI-BCMA BISPECIFIC T-CELL ENGAGER (BITE®) IMMUNOTHERAPY, IN R/R MULTIPLE MYELOMA (MM) PATIENTS: UPDATED RESULTS OF A FIRST-IN-HUMAN (FIH) PHASE 1 DOSE ESCALATION STUDY

H. Einsele, E. Rasmussen, J. Kalabus, 2019, HemaSphere.

Evaluation of AMG 420, an anti-BCMA bispecific T-cell engager (BiTE) immunotherapy, in R/R multiple myeloma (MM) patients: Updated results of a first-in-human (FIH) phase I dose escalation study.

H. Einsele, E. Rasmussen, J. Kalabus, 2019, Journal of Clinical Oncology.

Sulforaphane targets pancreatic tumour-initiating cells by NF-κB-induced antiapoptotic signalling

P. Altevogt, A. Kolb, M. Büchler, 2008, Gut.